Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine vs Cisplatin in Locally Advanced Cervical Cancer with Comorbidities
NCT06156514Phase 3Recruiting
- Sponsor
- Instituto Nacional de Cancerología
- Start
- Nov 2019
- Primary completion
- Nov 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of gemcitabine in Cervical Cancer (CC) (2 arms), sponsored by Instituto Nacional de Cancerología. Primary endpoint: Progression-Free Survival at 3 years. Started Nov 2019; status: recruiting.
02
Drugs
gemcitabine
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT06156514.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06156514.